Live from Eyecelerator at ASCRS 2024
Manage episode 411957897 series 3560279
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon.
Brought to you by Johns Hopkins University.
- Welcome to the Eyeluminaries podcast :21
- Review of episode 22 1:27
- Intro of Stephen Lane 2:41
- Intro of Terry Kim, MD 6:02
- Lane: Why retire? What’s next? 7:54
- Kim: Why the move to the industry? 10:35
- Lane: What does a chief medical officer do? What did you learn from the time you went from practice to CMO, and what were some of the surprises? 13:14
- Kim: What do you see as some of the challenges you will be facing? 18:19
- Lane: What will you miss the most about being a CMO? 21:03
- In your experience, how do you navigate transitions in a company and lead without losing focus? 24:22
- Preview of episode 24 30:45
- Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:34
- Thanks for listening 32:08
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center.
Stephen Lane is a founding partner of Associated Eye Care.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.
29 episod